


The background of the entire page is a dark navy blue. It is decorated with numerous thin, curved lines in various colors including red, orange, yellow, green, and blue. These lines sweep across the frame from the bottom left towards the top right, creating a sense of motion and energy.

**October
30th - 31st, 2025
SEVILLE**

SHAPING THE FUTURE
Controversies and Innovation in
Prostate Cancer Care

NH Collection Sevilla
Avda Diego Martinez Barrio, 8 - Seville, Spain

Scientific Directors

<i>Antonio Alcaraz</i>	University of Barcelona, Spain
<i>Alberto Bossi</i>	Amethyst Radiotherapy Group, Paris, France
<i>Elena Castro</i>	Hospital Universitario 12 de Octubre, Madrid, Spain

Scientific Rationale

Prostate cancer is one of the most prevalent male malignancies worldwide, characterized by significant biological and clinical heterogeneity. In recent years, the integration of big data into clinical research and the increasing availability of predictive tools have made clinical decision-making more complex. Furthermore, new scientific evidence is challenging long-established practices, such as indiscriminate therapeutic intensification or the routine adoption of active surveillance.

The structure of this event is designed to promote open discussion between different schools of thought, with the aim of fostering critical and shared reflections on the most effective and appropriate diagnostic-therapeutic pathways. The clinical debate sessions will provide participants with the opportunity to explore the pros and cons of key treatment strategies, while keynote lectures will offer an overview of the most relevant innovations. Finally, surgical video sessions will enable practical immersion into the intraoperative management of complex and atypical cases.

Speakers

<i>Antonio Alcaraz</i>	University of Barcelona, Spain
<i>Alberto Bossi</i>	Amethyst Radiotherapy Group, Paris, France
<i>Elena Castro</i>	Hospital Universitario 12 de Octubre, Madrid, Spain
<i>Vincenza Conteduca</i>	University of Foggia, Italy
<i>Susan Evans Axelsson</i>	EAU UroEvidenceHub, Arnhem, The Netherlands
<i>Freddie Hamdy</i>	University of Oxford, United Kingdom
<i>Steven Joniau</i>	Catholic University of Leuven, Belgium
<i>Pasquale Rescigno</i>	Newcastle University, United Kingdom
<i>Bertrand Tombal</i>	Cliniques Universitaires Saint-Luc, Brussels, Belgium
<i>Alessandro Volpe</i>	University of Eastern Piedmont, Novara, Italy
<i>Angela Lamont</i>	Scientific facilitator, London, United Kingdom

October 30th

13:45-14:00 Welcome and introduction *A. Alcaraz, A. Lamont*

14:00-14:45 **Keynote Lecture** **Big Data in Prostate Cancer** *S. Evans Axelsson*

From complexity to clinical insight

Discussion

Clinical Debate *Moderator: E. Castro*

14:45-15:45 Escalating vs de-escalating of therapy *V. Conteduca vs P. Rescigno*

How to navigate therapeutic intensity

Voting and discussion

15:45-16:15 Coffee break

Clinical Debate *Moderator: A. Alcaraz*

16:15-17:15 Radiotherapy in metastatic PCa: toward metastasis or prostate *A. Bossi vs B. Tombal*

Voting and discussion

Video Surgery Lecture

17:15-18:00 Insights and unusual findings in prostate surgery *A. Volpe*

A view from the operating room

Discussion

October 31st

09:00-09:15 Opening remarks *A. Alcaraz, A. Bossi, E. Castro*

09:15-10:00 **Keynote Lecture** **Personalized medicine in prostate cancer** *E. Castro*

Tailoring treatment in the era of precision care

Discussion

Video Surgery Lecture

10:00-10:45 Innovative surgical techniques in prostate cancer *A. Alcaraz*

Cutting-Edge innovations in the OR

Discussion

10:45-11:15 Coffee break

Clinical Debate *Moderator: A. Bossi*

11:15-12:15 Active surveillance vs Immediate treatment *S. Joniau vs F. Hamdy*

Managing early-stage prostate cancer

Voting and discussion

12:15-12:45 **Final Roundtable: Plenary discussion and wrap-up** *All speakers*

Looking ahead: insights, controversies, and unanswered questions

12:45-13:00 Conclusions and Take-home messages *A. Alcaraz, A. Bossi, E. Castro*

The background of the entire page is composed of numerous thin, curved lines in various colors including red, orange, yellow, green, and blue. These lines originate from the left side and curve towards the right, creating a sense of motion and depth.

Provider CME and secretariat

EURE||KA

Supported by an unrestricted
educational grant from

 **RECORDATI**

UEMS-EACCME accreditation

LEE/2025/01605



The **Shaping the Future. Controversies and Innovation in Prostate Cancer Care, Seville, Spain 30/10/2025 - 31/10/2025**, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **6.00** European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at <https://edhub.ama-assn.org/pages/applications>

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 22 of UEMS 2023.07.

In order to help you issue individual certificates to each participant, please find below the breakdown of ECMEC®s per day:

30/10/2025 - 3.0

31/10/2025 - 3.0

The EACCME® awards ECMEC®s on the basis of 0,5 ECMEC® for 30 minutes of CME with a maximum of 8 ECMEC®s per day. cf. Chapter XIII of UEMS 2023.07.